Press releases.

Press releases 2024

Press releases 2024

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

December 17th 2024

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

December 16th 2024

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

December 12th 2024

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

December 10th 2024

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

November 14th 2024

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

November 14th 2024

Immutep Quarterly Activities Report Q1 FY25

October 29th 2024

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

October 28th 2024

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

October 17th 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

October 10th 2024

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

October 3rd 2024

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

September 24th 2024

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

September 18th 2024

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

September 16th 2024

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

August 20th 2024

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

August 14th 2024

Immutep to Participate in Upcoming Investor Conferences

August 7th 2024

Immutep Quarterly Activities Report Q4 FY24

July 31st 2024

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

July 22nd 2024

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

July 17th 2024

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

July 12th 2024

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

July 3rd 2024

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer

June 27th 2024

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

June 25th 2024

Immutep successfully completes institutional placement and institutional component of entitlement offer

June 5th 2024

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

June 3rd 2024

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15th 2024

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2nd 2024

Immutep Quarterly Activities Report Q3 FY24

April 29th 2024

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

April 24th 2024

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

April 18th 2024

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

April 17th 2024

Immutep Announces First Clinical Data from 90mg Dosing of Efti

March 5th 2024

Immutep Quarterly Activities Report Q2 FY24

January 30th 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

January 4th 2024